OBJECTIVES The purpose of this study was to assess the benefit of primary prevention implantable cardioverter defibrillators (ICDs) in women.
R
andomized clinical trials demonstrating a benefit of primary prevention implantable cardioverter-defibrillators (ICDs) comprised only 10% to 30% women (1) (2) (3) (4) . This lack of trial information, in part, led some to question whether primary prevention ICDs are beneficial in women; however, ICD recommendations in practice guidelines make no distinction between women and men (5, 6) . Studies have subsequently demonstrated substantially lower use of primary prevention ICDs in women seen in clinical practice (7, 8) . This disparity is likely multifactorial and may be in part caused by the lack of definitive data on the survival benefit of ICDs in women. Indeed, various retrospective and post-hoc analyses of existing trial data have produced conflicting results (9) (10) (11) (12) (13) (14) .
A Canadian registry-based study of a combined primary and secondary prevention ICD population demonstrated a wide sex differential in referrals for ICD but similar survival rates among men and women with an ICD (15) . In addition, a recent single-center study matched men and women with ICDs by propensity score and found that mortality benefit was similar (16) . Other comparisons of the mortality benefit associated with ICDs between men and women have reached similar conclusions (17, 18) .
However, to date, there has been no large multicenter analysis comparing survival in eligible women with and without a primary prevention ICD. Although ideally one would conduct an adequately powered randomized clinical trial to address this specific question, such a trial is highly unlikely because of the associated cost and ethical challenges.
Therefore, this analysis of women in the National Cardiovascular Data Registry (NCDR) and American Heart Association (AHA) Get With The GuidelinesHeart Failure (GWTG-HF) database was conducted to examine the survival difference between women with a primary prevention ICD and eligible women with no ICD. Indeed, one of the primary goals of the NCDR is to determine whether the randomized controlled trial findings can be applied to subpopulations of interest, including women (19) . 
Zeitler et al. Baseline characteristics of patients with and without ICDs were expected to be quite different; this was confirmed with preliminary examination of the data.
Therefore, a matching process was planned and employed using the Rosenbaum and Rubin method to derive a set of patients without ICDs similar to the sample of patients with ICDs (the smaller group) (27) . After accounting for missing values, propensity models were built for men and women using baseline characteristics deemed to be potentially clinically Baseline characteristics in men for a similar analysis were different before matching (Online Table) . Men without ICDs were older and more frequently white; they had different prevalences of diabetes and hypertension. Rates of medical therapy with calcium Zeitler et al.
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After matching, the group characteristics became similar for women and men. Baseline characteristics in the matched groups are shown in Table 1 and Online Table, Table 2) . As Table 2 and Figures 2 and 3 demonstrate, the mortality difference between the 2 groups of women was evident early, with adjusted mortality at 1 year of 21.7% in the patients with ICDs and 28.3% in the patients without ICDs, and this difference was maintained throughout the course of follow-up, with adjusted mortality at 3 years of 44.3% in the group with ICDs and 54.5% in the group without ICDs (Figures 2 and 3) . Overall, the hazard of mortality in women with an ICD was significantly lower than that Outcomes were examined by age tertile ( Table 3 ).
Tertile cutoffs were slightly different for men and women, reflecting a small shift in women from patients in their late 60s to patients in their 70s. We further tested for a 3-way interaction between sex, age (by tertile), and the presence of an ICD in relation to mortality risk. This showed no interaction (p ¼ 0.55).
DISCUSSION
In this analysis, we found that among older women with depressed LVEF hospitalized for HF, implantation of a guideline-supported primary prevention ICD was associated with a significant survival advantage, similar in magnitude to that seen in men. The adjusted HR for mortality in the group with ICDs compared with the group without ICDs in our study was 0.79 for women and 0.73 for men. These adjusted HRs are consistent with results observed in randomized clinical trials that support the use of primary prevention ICDs in HF patients (1, 4) . Unlike what was observed in those clinical trials, in our study, the survival curves for women with an ICD versus women with no ICD separated early, likely because of the higher event rates in our population (1, 2) . Indeed, the mortality rates in follow-up of both groups in this analysis were higher than those seen in (28) . In addition, the cohorts in our analysis were, on average, more than 10 years older than those studied in randomized clinical trials. This is why we looked for an interaction between age, sex, and ICD, which was not significant. This high p value supports the conclusion that if an interaction exists between age and the presence of an ICD in relation to mortality risk, it is consistent across sexes. The unadjusted cumulative risk of death in women with an implantable cardioverterdefibrillator (ICD) was less than that of women without an ICD. This difference was evident at 1 year and persisted throughout the course of follow-up.
Zeitler et al.
JACC: HEART FAILURE VOL. 3, NO. 2, 2015 ICDs in Women Despite the dynamic and subjective nature of this variable, it may be a potential confounder. All variables that were available in both datasets that may be surrogates for HF severity were included: LVEF, systolic blood pressure, and prior atrial arrhythmias ( Table 1 ). The source of data for the non-ICD population was hospitals that participated voluntarily in the GWTG-HF for quality improvement. As such, patients who qualified for a primary prevention ICD but did not receive one may have had a comorbid condition not captured in our analysis that made them both at higher risk for mortality and less appropriate for ICD implantation. Also, we excluded patients who received a CRT device. Primary prevention ICD trials were conducted at a time before CRT was widely implemented, so some patients who would now be eligible for CRT were included in those trials.
Their exclusion from our analysis may result in some alkha001@mc.duke.edu.
